Albumin Administration in Malignant Pleural Effusion
Albumin is NOT indicated for the routine management of malignant pleural effusion. The major pleural disease guidelines make no recommendation for albumin use in MPE, and FDA labeling does not list MPE as an indication for albumin therapy 1.
When Albumin Should NOT Be Used
Albumin should not be used to treat chronic hypoalbuminemia in cancer patients with MPE. The FDA explicitly states that albumin is not justified for treating "stabilized hypoproteinemia accompanying chronic cirrhosis, chronic nephrosis, protein-losing enteropathy, malabsorption and pancreatic insufficiency" 1. This principle extends to cancer-related hypoalbuminemia, as albumin is not an appropriate intravenous nutrient and does not address the underlying malignancy 1.
Evidence-Based Management of MPE
The 2023 British Thoracic Society and 2018 ATS/STS/STR guidelines provide clear management pathways that do not include albumin 2, 3:
- For symptomatic patients with expandable lung: Use either indwelling pleural catheter (IPC) or talc pleurodesis as first-line therapy
- For nonexpandable lung or failed pleurodesis: Use IPC over chemical pleurodesis
- For asymptomatic patients: Do not perform therapeutic pleural interventions
The Only Potential Exception
Albumin might be considered only if acute hemodynamic instability occurs during large-volume thoracentesis, though this is rare and not specifically addressed in pleural guidelines. The FDA indicates albumin use is "usually appropriate" for shock and acute volume deficits 1. However, crystalloid solutions are typically sufficient for volume resuscitation in this setting.
Important Clinical Context
Hypoalbuminemia Does Not Cause Pleural Effusion
Research demonstrates that hypoalbuminemia alone rarely causes pleural effusion. In a prospective study of 68 patients with albumin ≤3.5 g/dL, none had unexplained pleural effusions—all had identifiable alternative causes 4. The presence of low albumin in MPE patients reflects the underlying malignancy and systemic illness, not a therapeutic target.
Albumin as a Prognostic Marker, Not a Treatment Target
Recent data shows that serum albumin <3.0 g/dL independently predicts poorer survival in MPE patients (HR: 1.60, P=0.040) 5. However, this identifies high-risk patients rather than indicating albumin replacement. One small case series noted that low albumin (1.7 g/dL) combined with high-dose steroids may reduce pleurodesis success 6, but this does not justify routine albumin administration.
Clinical Pitfalls to Avoid
- Do not give albumin to "improve nutrition" in cachectic cancer patients with MPE—it is ineffective and wastes resources 1
- Do not confuse diagnostic albumin gradients with therapeutic indications—the serum-effusion albumin gradient helps classify effusions but does not indicate albumin therapy 7
- Do not delay definitive pleural intervention (IPC or pleurodesis) to "optimize" albumin levels first
Bottom Line Algorithm
- Symptomatic MPE with expandable lung → IPC or talc pleurodesis (patient preference, clinical factors)
- Symptomatic MPE with nonexpandable lung → IPC
- Asymptomatic MPE → Observation, no intervention
- Hemodynamic instability during thoracentesis → Crystalloid first; albumin only if refractory shock
Albumin has no role in steps 1-3, which encompass >95% of MPE management.